Rate and Equilibrium Constants for the Epimerization of the Endothelin Receptor Antagonist J-104,132 in Aqueous Solution.
-
- BRAY Michelle L.
- Pharmaceutical Research and Development, Merck Research Laboratories
-
- GORBACHEVA Daniela
- Pharmaceutical Research and Development, Merck Research Laboratories
-
- JAHANSOUZ Hossain
- Pharmaceutical Research and Development, Merck Research Laboratories
-
- KAUFMAN Michael J.
- Pharmaceutical Research and Development, Merck Research Laboratories
-
- ISHIKAWA Kiyofumi
- Pharmaceutical Research and Development, Laboratories for Technology Development, Banyu Pharmaceutical Co., Ltd.
-
- HARADA Nobuo
- Pharmaceutical Research and Development, Laboratories for Technology Development, Banyu Pharmaceutical Co., Ltd.
-
- SUZUKI Kimimasa
- Pharmaceutical Research and Development, Laboratories for Technology Development, Banyu Pharmaceutical Co., Ltd.
Bibliographic Information
- Other Title
-
- Rate and Equilibrium Constants for the Epimerization of the Endothelin Receptor Antagonist J-104,132 Aqueous Solution
Search this article
Abstract
The degradation of [5S-[5α, 6β, 7α(R*)]]-2-butyl-5-(1, 3-benzodioxol-5-yl)-7-[(2-carboxypropyl)-4-methoxy-phenyl]-6-dihydro-5H-cyclopenta[b]pyridine-6-carboxylic acid (J-104, 132) was studied in aqueous solution as a function of temperature and pH. The degradation reaction does not proceed to completion; rather, a stable equilibrium is attained in which approximately 2% of the degradate is produced. Kinetic data for the formation of the degradate are analyzed using an integrated form of the rate law for a reversible first-order reaction, and the forward and reverse rate constants and overall equilibrium constants are presented. Isolation and spectroscopic structural determination indicate that the degradate is the C7 β-epimer of the drug. A mechanism for the epimerization reaction involving a novel enamine-like intermediate is proposed and shown to be consistent with the kinetic data. The rate and equilibrium constants are used to predict the room temperature stability of an injectable formulation of J-104, 132, and these predictions are compared to actual data from long-term stability studies. It is concluded that the preformulation kinetic studies provide essential data needed for optimum drug product development.
Journal
-
- Chemical and Pharmaceutical Bulletin
-
Chemical and Pharmaceutical Bulletin 49 (1), 1-4, 2001
The Pharmaceutical Society of Japan
- Tweet
Details 詳細情報について
-
- CRID
- 1390001204162430464
-
- NII Article ID
- 110003615743
-
- NII Book ID
- AA00602100
-
- DOI
- 10.1248/cpb.49.1
-
- COI
- 1:CAS:528:DC%2BD3MXkvVanug%3D%3D
-
- ISSN
- 13475223
- 00092363
-
- NDL BIB ID
- 5622262
-
- PubMed
- 11201209
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed